Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Tue, 21 Jul 2026 08:45:00 -0400

The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment.
Secondary objectives include assessment of the overall safety and tolerability.
The trial will employ a seamless adaptive Phase II/III design, incorporating an interim analysis following completion of Phase II to allow a seamless transition into the confirmatory Phase III portion of the program.
Devonian believes Thykamine™ has the potential to provide an important new non-steroidal therapeutic option for pediatric patients requiring long-term disease management.

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

QUÉBEC, June 29, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026.

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Mon, 29 Jun 2026 20:00:00 -0400

(all amounts are in Canadian dollars)

Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
Cash as of April 30, 2026, $0.7 million
Company remains debt-free

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Mon, 30 Mar 2026 16:00:00 -0400

QUÉBEC, March 30, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on March 27, 2026 (the "Meeting") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Mon, 30 Mar 2026 16:00:00 -0400

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Mon, 30 Mar 2026 16:00:00 -0400

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Mon, 30 Mar 2026 16:00:00 -0400

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Mon, 30 Mar 2026 16:00:00 -0400

StreetInsider.com News Articles

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Year

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Reports Results of its Annual General and Special Meeting of Shareholders